Thailand Medical Device Market Size, Share & Forecast, By Product Type, End User & Distribution Channel, 2025–2032

The Thailand Medical Devices Market was valued at USD 8,493 million in 2025 on a domestic-consumption basis. The estimate is anchored to Thailand's apparent-consumption structure, official 2024 market data and 2025 operating indicators showing positive domestic medical-device sales despite softer trade flows. The market includes domestically supplied and imported medical devices consumed in Thailand while excluding exported production from domestic market value. Thailand's established hospital system, 648 listed manufacturers and high-value import channel support a market substantially larger than most neighboring ASEAN economies.

The market is projected to reach USD 11,698 million by 2032, representing a 4.68% CAGR from the 2025 base. Near-term growth remains more moderate, consistent with industry expectations for approximately 2.5-3.5% annual domestic sales expansion during 2026-2028. Growth is modeled to strengthen later as higher-value durable equipment, connected monitoring, AI-assisted diagnostics and home-care devices gain share. The forecast therefore assumes greater value growth per device rather than a return to pandemic-era volume spikes in basic consumables and testing products.

Profit pools are expected to shift toward durable, connected and clinically differentiated devices. Thailand's domestic manufacturing base remains strongest in single-use products, while high-value imaging, cardiovascular, robotic and electro-diagnostic technologies rely more heavily on multinational suppliers and imported technology. Durable devices represented 38.1% of medical-device imports during 9M25 and were the only major import category to record positive growth during that period. Service contracts, software, consumables attached to installed systems and clinical training therefore become increasingly important components of lifetime customer value.

The principal risk is competing profitably while managing regulatory requirements and dependence on imported advanced technology. The market uses four medical-device risk classes, with higher-risk products requiring more extensive regulatory submissions. At the same time, domestic manufacturers compete aggressively in standardized consumables, while multinational suppliers retain technology advantages in sophisticated equipment. Manufacturing capacity utilization reached only 58.9% during 8M25, indicating that capacity alone does not guarantee attractive returns. Clinical acceptance, after-sales support, tender discipline and regulatory execution are therefore critical to defensible market entry.

Thailand has a larger modeled domestic market than Indonesia, Vietnam, Malaysia and the Philippines in the peer set used in this report, although some smaller markets are growing faster. Vietnam's medical-device market was USD 1.9 billion in 2024 and was forecast to grow 8.2% annually through 2029, while Indonesia's 2025 market estimate was USD 2.779 billion. Thailand's advantage is the combination of domestic scale, export manufacturing depth, medical tourism and advanced hospital infrastructure rather than the region's highest percentage growth rate.

Population aging is the most durable structural demand factor. Approximately 20.36% of Thailand's population, equivalent to about 13 million people, was already over 60, and the proportion is expected to rise materially through the forecast period. Aging increases the prevalence and duration of cardiovascular, metabolic, mobility, respiratory and neurological care needs. It also shifts device utilization outside tertiary hospitals into rehabilitation facilities, elderly-care businesses and patient homes, expanding demand for monitoring, mobility aids, respiratory devices and chronic-disease management technology.

Localization is strategically important but will be selective rather than universal. Thailand already has 648 manufacturers listed by the Medical Devices Intelligence Unit, yet local production remains concentrated in consumables and comparatively straightforward devices. Government policy is therefore moving toward higher-value testing, certification and commercialization capabilities, including compact CT, digital radiography and active medical-device testing. BOI incentives can support qualifying healthcare manufacturing investment, while localization reduces lead times and import exposure. However, advanced intellectual property, component supply, clinical evidence and service capability remain barriers to rapid substitution.